---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-23-000072"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:09:42.820346+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics Q3 net income $35.5M; initiates Phase 1 for DMD candidate ENTR-601-44

## Summary
- Net income of $35.5M in Q3 2023 vs net loss of $(25.1M) in Q3 2022, driven by $43.7M collaboration revenue.
- Cash, cash equivalents and securities of $353.6M as of Sep 30, 2023; runway expected through 2025.
- Dosed first participant in Phase 1 trial of ENTR-601-44 for Duchenne muscular dystrophy; data expected H2 2024.
- Selected third Duchenne candidate ENTR-601-50 with IND/CTA planned for 2025; preclinical data expected H1 2024.
- Achieved Vertex milestone triggering $17.5M payment; entered license for ENTR-501 with Pierrepont Therapeutics.

## SEC filing metadata
- accession: 0001689375-23-000072
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000072/0001689375-23-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000072/trda-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-23-000072
- JSON: https://secwatch.observer/filing/0001689375-23-000072.json
- Plain text: https://secwatch.observer/filing/0001689375-23-000072.txt

## Key facts
- Earnings Releases
  Entrada Therapeutics, Inc. reported third quarter ending September 30, 2023 results: revenue $43.7 million, net income $35.5 million.
  - Period: third quarter ending September 30, 2023
  - Revenue: $43.7 million
  - Net income: $35.5 million
  - Result: reported results
  source text: milestones, will be sufficient to fund the Company's operating expenses and capital expenditure requirements through 2025. Collaboration Revenue: Collaboration revenue was $43.7 million for the third quarter of 2023. There was no collaboration revenue in the third quarter of 2022. Research & Development (R&D) Expenses: R&D expenses were $22.2 million for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000072/0001689375-23-000072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.